文献速递鼻科小儿耳鼻咽喉

囊性纤维化患者慢性鼻窦炎 upfront 手术与药物治疗的决定因素与结局

Determinants and outcomes of upfront surgery versus medical therapy for chronic rhinosinusitis in cystic fibrosis.
PubMed 文献 · Int Forum Allergy Rhinol · 2017-02-20

回顾性分析 136 例转诊至三级鼻科门诊的囊性纤维化(CF)患者,分为药物组、upfront 手术组和交叉组。结果显示 upfront 手术组鼻息肉、既往鼻窦手术比例更高,%FEV1 更低,Lund-Mackay 和 SNOT-22 评分更高;药物组 35.5% 平均 14.3 个月后转手术,交叉组 SNOT-22 增加 6.1 分、%FEV1 下降 4.5%;手术可有效减轻 CRS 相关症状但可能不改善肺功能。

要点

  • upfront 手术组较药物组鼻息肉、既往鼻窦手术比例更高,%FEV1 更低,Lund-Mackay 和 SNOT-22 评分更高。
  • 药物组 35.5% 平均 14.3 个月后转为手术,交叉组 SNOT-22 增加 6.1 分、%FEV1 下降 4.5%。
  • 手术可有效减轻 CF 患者 CRS 相关症状,但可能不改善肺功能。

核心结论

  • 手术可有效减轻 CF 患者 CRS 相关症状,但可能不改善肺功能。
  • 先接受药物治疗的患者症状恶化可能促使最终转为手术。
  • 延迟手术的患者可能获得与 upfront 手术相似的结果。

研究设计与样本

  • 回顾性研究,将 136 例转诊至三级鼻科门诊的 CF 患者分为药物组、upfront 手术组和交叉组(由药物转为手术)。
  • 评估 SNOT-22 和肺功能检查(PFT)数据至 48 个月。

主要发现

  • 与初始药物治疗患者(n=90)相比,upfront 手术患者(n=46)鼻息肉发生率更高(p=0.0011)、既往鼻窦手术比例更高(p=0.0025)、%FEV1 更低(p=0.0063)、Lund-Mackay 评分更高(p=0.0025)、SNOT-22 评分更高(p=0.0229)。
  • 药物组中 35.5% 平均 14.3 个月后转为手术。
  • 交叉组(n=32)SNOT-22 增加 6.1 分、%FEV1 下降 4.5%。
  • 交叉组术后 SNOT-22 评分(p=0.831)和 %FEV1(p=0.114)与 upfront 手术组相似。
  • 药物组基线 SNOT-22 评分最低(p<0.001),但任何时间的手术均使评分恢复至相同基线水平(p=0.652)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The indications for surgical management of chronic rhinosinusitis (CRS) in patients with cystic fibrosis (CF) are poorly defined. In this study we compare outcomes of medical versus surgical treatment and examine trends associated with the transition from medical to surgical therapy in CF patients. METHODS: One hundred thirty-six patients with CF referred to a tertiary rhinology practice were retrospectively divided into 3 cohorts: Medical, Upfront Surgery, or Crossover, if they converted from medical to surgical management. The 22-item Sino-Nasal Outcome Test (SNOT-22) and pulmonary function test (PFT) data were assessed up to 48 months. RESULTS: Compared to patients initially managed medically (n = 90), those who pursued upfront surgery (n = 46) had a greater incidence of nasal polyposis (p = 0.0011), prior sinus surgery (p = 0.0025), lower percent-predicted forced expiratory volume in 1 second (%FEV1 ) (p = 0.0063), and higher Lund-Mackay (p = 0.0025) and SNOT-22 (p = 0.0229) scores. Within the medical group, 35.5% converted to surgery after a mean of 14.3 months. Crossover (n = 32) was associated with a 6.1-point increase in SNOT-22 and a 4.5% deterioration in %FEV1 . Despite worsened symptom severity, the Crossover cohort ultimately achieved similar postoperative SNOT-22 scores (p = 0.831) and %FEV1 (p = 0.114) as those who underwent upfront surgery. Although the Medical cohort had the lowest baseline SNOT-22 scores (p < 0.001), surgery at any time normalized scores to the same baseline level (p = 0.652). Neither medical therapy nor surgery improved PFTs. CONCLUSIONS: Surgery effectively reduces CRS-related symptoms in CF patients but may not improve pulmonary function. In patients who first pursue medical therapy, symptomatic decline may prompt eventual conversion to surgery. Patients who delay surgery may achieve similar outcomes as those who pursue surgery upfront.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Ayoub N, Thamboo A, Habib AR, et al. Determinants and outcomes of upfront surgery versus medical therapy for chronic rhinosinusitis in cystic fibrosis. Int Forum Allergy Rhinol. 2017. PMID: 28218486. doi:10.1002/alr.21912

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。